AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26232169 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison (women vs men)
Number of subjects: 30
Study 26232169 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal × time interaction
Number of subjects: 30
Study 26232169 — intervention group
Group type: COMPARATOR
Intervention: Plasma D-dimer, interleukin-6, interleukin-1β, tumor necrosis factor-α, high sensitivity C-reactive protein
Number of subjects: 30
Study 23925740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless unicompartmental knee replacement
Number of subjects: 62
Study 23925740 — intervention group
Group type: COMPARATOR
Intervention: Cemented unicompartmental knee replacement
Number of subjects: 62
Study 21743067 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE) anaesthesia
Number of subjects: 70
Study 21743067 — intervention group
Group type: COMPARATOR
Intervention: Non-pharmacological methods of pain relief
Number of subjects: 70
Study 19404671 — intervention group
Group type: EXPERIMENTAL
Intervention: Calisthenic training (CT)
Number of subjects: 16
Study 19404671 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 16
Study 16688841 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral or enteral nutrition (24.6±5.2 kcal/kg per day non-protein and 0.23±0.04 g nitrogen/kg per day)
Number of subjects: 468
Study 16688841 — intervention group
Group type: COMPARATOR
Intervention: Control group (600±100 kcal non-protein plus or not plus 62±16 g crystalline amino acids postoperatively)
Number of subjects: 468
Study 16688841 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 468
Study 16688841 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition group
Number of subjects: 468
Study 15474852 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious participants watching a video of an actor portraying anxious affect
Number of subjects: 208
Study 15474852 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphoric participants watching a video of an actor portraying depressed affect
Number of subjects: 208
Study 15474852 — intervention group
Group type: COMPARATOR
Intervention: Control participants watching a video of an actor portraying neutral affect
Number of subjects: 208
Study 15474852 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants (anxious, dysphoric, and control) watching a video of an actor portraying depressed affect
Number of subjects: 208
Study 11770696 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension 0.25 mg, 0.5 mg, or 1.0 mg once daily for 12 weeks
Number of subjects: 0
Study 11770696 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (all doses)
Number of subjects: 0
Study 11770696 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (0.25 mg)
Number of subjects: 0
Study 11770696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9792256 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive polymerase chain reaction tests for C. pneumoniae
Number of subjects: 282
Study 7973476 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive dynamic strength training (EG)
Number of subjects: 39
Study 7973476 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 39
Study 2638954 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine mouthwash
Number of subjects: 14
Study 2638954 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthwash
Number of subjects: 14
Study 30321909 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 100
Study 30321909 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab (4 doses)
Number of subjects: 100
Study 30321909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 28028318 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone undecanoate (n=49)
Number of subjects: 100
Study 28028318 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=51)
Number of subjects: 100
Study 25597607 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy (PP) performed on patients in Group A.
Number of subjects: 207
Study 25597607 — intervention group
Group type: COMPARATOR
Intervention: Control group (no posterior pericardiotomy) in Group B.
Number of subjects: 207
Study 23363466 — intervention group
Group type: EXPERIMENTAL
Intervention: Email prompt after 2 weeks
Number of subjects: 240
Study 23363466 — intervention group
Group type: EXPERIMENTAL
Intervention: Email prompt after 4 weeks
Number of subjects: 240
Study 23363466 — intervention group
Group type: EXPERIMENTAL
Intervention: Email prompt after 6 weeks
Number of subjects: 240
Study 23363466 — intervention group
Group type: EXPERIMENTAL
Intervention: Email prompt with additional content
Number of subjects: 240
Study 23363466 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional email prompt)
Number of subjects: 240
Study 21912927 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking training in the morning
Number of subjects: 40
Study 21912927 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking training in the evening
Number of subjects: 40
Study 21912927 — intervention group
Group type: COMPARATOR
Intervention: Sleep following training
Number of subjects: 40
Study 21912927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical excitability measures
Number of subjects: 40
Study 19463300 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 310
Study 19463300 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 310
Study 16490804 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 tablets of erlotinib 25 mg
Number of subjects: 62
Study 16490804 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 tablet of erlotinib 150 mg
Number of subjects: 62
Study 16490804 — intervention group
Group type: COMPARATOR
Intervention: 25 mg intravenous infusion of erlotinib
Number of subjects: 62
Study 12620563 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical oncology fellowship (SO)
Number of subjects: 201
Study 12620563 — intervention group
Group type: COMPARATOR
Intervention: General surgery training (GS)
Number of subjects: 201
Study 12620563 — intervention group
Group type: COMPARATOR
Intervention: Other fellowships (OF)
Number of subjects: 201
Study 11073286 — intervention group
Group type: EXPERIMENTAL
Intervention: Closerin capsules (250 mg)
Number of subjects: 24
Study 11073286 — intervention group
Group type: COMPARATOR
Intervention: Dura seromycin capsules (250 mg)
Number of subjects: 24
Study 9196315 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin coated cardiopulmonary bypass (n = 56)
Number of subjects: 120
Study 9196315 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 59)
Number of subjects: 120
Study 8446653 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 21
Study 3536389 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate enemas
Number of subjects: 60
Study 3536389 — intervention group
Group type: COMPARATOR
Intervention: Sorbit enemas
Number of subjects: 60
Study 29422475 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC) (EQUIA; GC)
Number of subjects: 40
Study 29422475 — intervention group
Group type: COMPARATOR
Intervention: Microhybrid resin composite (Amelogen Plus; Ultradent)
Number of subjects: 40
Study 26482398 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice education program for 4 weeks followed by 4 weeks of continued practice
Number of subjects: 127
Study 26482398 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 127
Study 24488359 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound
Number of subjects: 20
Study 24488359 — intervention group
Group type: COMPARATOR
Intervention: Conventional localization
Number of subjects: 20
Study 23027068 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based home exercise programme (n = 43), 12 weeks, 4 days per week at the hospital
Number of subjects: 81
Study 23027068 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 38), waiting list
Number of subjects: 81
Study 19423094 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroejaculation or penile vibrating stimulation semen cryopreservation using a commercial TEST‐yolk‐buffer technique
Number of subjects: 0
Study 19423094 — intervention group
Group type: COMPARATOR
Intervention: Control group (men without spinal cord injury)
Number of subjects: 0
Study 18534880 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional full-time patching
Number of subjects: 57
Study 18534880 — intervention group
Group type: COMPARATOR
Intervention: Atropine penalization
Number of subjects: 57
Study 15951468 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (0.75-10 mg/d) for 28 days
Number of subjects: 0
Study 15951468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12477672 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA containing 20 mg tramadol + 1 mg metoclopramide per millilitre (Group T+M)
Number of subjects: 40
Study 12477672 — intervention group
Group type: COMPARATOR
Intervention: PCA containing 20 mg tramadol (Group T)
Number of subjects: 40
Study 15499886 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit rule‐based instruction approach
Number of subjects: 40
Study 15499886 — intervention group
Group type: COMPARATOR
Intervention: Basal‐reader activity‐based approach
Number of subjects: 40
Study 8953628 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural networks using clinical and pathological data
Number of subjects: 81
Study 8953628 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural networks with additional specialized markers
Number of subjects: 81
Study 1672802 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of vecuronium (2.5 X ED95)
Number of subjects: 32
Study 1672802 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose of vecuronium (1 X ED95)
Number of subjects: 32
Study 7316031 — intervention group
Group type: EXPERIMENTAL
Intervention: Open (Penrose) drainage
Number of subjects: 122
Study 7316031 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed sump drainage
Number of subjects: 122
Study 7316031 — intervention group
Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 122
Study 31992407 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Restriction Therapy (SRT) - 2 sessions with interim phone contact
Number of subjects: 150
Study 31992407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) - 6 sessions
Number of subjects: 150
Study 31992407 — intervention group
Group type: COMPARATOR
Intervention: Sleep Education Control - 6 sessions
Number of subjects: 150
Study 31075059 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced respiration
Number of subjects: 161
Study 31075059 — intervention group
Group type: COMPARATOR
Intervention: Control (music listening)
Number of subjects: 161
Study 28558147 — intervention group
Group type: EXPERIMENTAL
Intervention: SinuBand FP
Number of subjects: 30
Study 28558147 — intervention group
Group type: COMPARATOR
Intervention: SinuBand (without FP)
Number of subjects: 30
Study 28558147 — intervention group
Group type: COMPARATOR
Intervention: Merocel (standard nasal pack)
Number of subjects: 30
Study 26466681 — intervention group
Group type: EXPERIMENTAL
Intervention: Education messages for schistosomiasis prevention + pre-treatment snack (2013)
Number of subjects: 12
Study 26466681 — intervention group
Group type: COMPARATOR
Intervention: Education messages for schistosomiasis prevention (2013)
Number of subjects: 12
Study 26466681 — intervention group
Group type: EXPERIMENTAL
Intervention: Education messages for schistosomiasis prevention + pre-treatment snack (2014)
Number of subjects: 12
Study 26466681 — intervention group
Group type: COMPARATOR
Intervention: Education messages for schistosomiasis prevention (2014)
Number of subjects: 12
Study 26466681 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of S. mansoni infection (2013)
Number of subjects: 12
Study 26466681 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of S. mansoni infection (2014)
Number of subjects: 12
Study 26466681 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric mean intensity of S. mansoni infection (2013)
Number of subjects: 12
Study 26466681 — intervention group
Group type: EXPERIMENTAL
Intervention: Geometric mean intensity of S. mansoni infection (2014)
Number of subjects: 12
Study 22420871 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus 1.2% SMV
Number of subjects: 38
Study 22420871 — intervention group
Group type: COMPARATOR
Intervention: SRP plus placebo
Number of subjects: 38
Study 21164500 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper tertile for previous dietary adherence
Number of subjects: 116
Study 19763023 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined photodynamic therapy (PDT) and sub-Tenon's capsule injection of 20 mg triamcinolone acetonide (TA)
Number of subjects: 117
Study 19763023 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT) alone
Number of subjects: 117
Study 19763023 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PDT and TA
Number of subjects: 117
Study 19763023 — intervention group
Group type: COMPARATOR
Intervention: PDT alone
Number of subjects: 117
Study 17124018 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin plus a glycoprotein IIb/IIIa inhibitor
Number of subjects: 13819
Study 17124018 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin alone
Number of subjects: 13819
Study 17124018 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus a glycoprotein IIb/IIIa inhibitor
Number of subjects: 13819
Study 15582343 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet with pictograms
Number of subjects: 90
Study 15582343 — intervention group
Group type: COMPARATOR
Intervention: Leaflet with plain text
Number of subjects: 90
Study 11265775 — intervention group
Group type: EXPERIMENTAL
Intervention: MUC1‐mannan fusion protein (M‐FP) administered at doses of 1 to 300 microg, given intramuscularly in trial 1 and intraperitoneally in trial 2, with immunizations at weekly intervals (weeks 1 to 3) and repeated in weeks 7 to 9. Cyclophosphamide was given on weeks 1 and 4.
Number of subjects: 41
Study 11265775 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (to increase cellular immunity)
Number of subjects: 41
Study 9427901 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone therapy
Number of subjects: 29
Study 9427901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 8279757 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 184
Study 8279757 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary radiotherapy
Number of subjects: 184
Study 8279757 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-SPF tumors
Number of subjects: 184
Study 8279757 — intervention group
Group type: EXPERIMENTAL
Intervention: High-SPF nonresponders
Number of subjects: 184
Study 3334236 — intervention group
Group type: EXPERIMENTAL
Intervention: Short plantar splint
Number of subjects: 300
Study 3334236 — intervention group
Group type: COMPARATOR
Intervention: Spica strapping
Number of subjects: 300
Study 30095791 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly teriparatide administration starting at 1 week postoperatively
Number of subjects: 66
Study 30095791 — intervention group
Group type: COMPARATOR
Intervention: No teriparatide administration (control group)
Number of subjects: 66
Study 30095791 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly teriparatide administration
Number of subjects: 66
Study 30095791 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anterior slippage of the cranial vertebra next to fusion segment < 2 mm
Number of subjects: 66
Study 30094335 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine administration
Number of subjects: 24
Study 30094335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26687339 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg, once a night) plus rosuvastatin (10mg, once a night)
Number of subjects: 106
Study 26687339 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin alone (10mg, once a night)
Number of subjects: 106
Study 24661107 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR plus LLLT (1064 nm, 100 mW, energy density of 4 J/cm²)
Number of subjects: 13
Study 24661107 — intervention group
Group type: COMPARATOR
Intervention: GTR alone
Number of subjects: 13
Study 22079604 — intervention group
Group type: EXPERIMENTAL
Intervention: Music and local anesthesia
Number of subjects: 26
Study 22079604 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia alone
Number of subjects: 26
Study 22079604 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study 20590479 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) intervention, administered for five 1-minute bouts per session, 3 days per week, for 6 weeks
Number of subjects: 37
Study 20590479 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON), asked not to commence any form of physical training
Number of subjects: 37
Study 18399868 — intervention group
Group type: EXPERIMENTAL
Intervention: MTB12 Ag
Number of subjects: 0
Study 18399868 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MTB12 and 38-kDa Ag
Number of subjects: 0
Study 18399868 — intervention group
Group type: EXPERIMENTAL
Intervention: MTB12 Ag plus 38-kDa Ag
Number of subjects: 0
Study 18399868 — intervention group
Group type: EXPERIMENTAL
Intervention: MTB12 Ag plus 30-kDa Ag
Number of subjects: 0
Study 15807812 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical irritation during work in the dispatch department
Number of subjects: 71
Study 12437705 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture with needles placed at the Shen Men, Thalamus, Tranquiliser and Master Cerebral Points on the right ear
Number of subjects: 10
Study 12437705 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 10
Study 10494774 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular low to moderate intensity physical activity
Number of subjects: 132
Study 10494774 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention reference group
Number of subjects: 132
Study 8766893 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.18 to 1.1 g per day of long‐chain polyunsaturated omega‐3 fatty acids (fish oil capsules)
Number of subjects: 20
Study 1672530 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl palmitate (300,000 IU daily for 12 months)
Number of subjects: 283
Study 1672530 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up
Number of subjects: 283
Study 6126871 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine
Number of subjects: 60
Study 6126871 — intervention group
Group type: EXPERIMENTAL
Intervention: chlorpheniramine maleate
Number of subjects: 60
Study 6126871 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 31595600 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg galcanezumab
Number of subjects: 129
Study 31595600 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg galcanezumab
Number of subjects: 129
Study 31595600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 29749316 — intervention group
Group type: EXPERIMENTAL
Intervention: Group spiritual intervention (10 sessions)
Number of subjects: 60
Study 29749316 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 28108936 — intervention group
Group type: EXPERIMENTAL
Intervention: GMCB (group-mediated cognitive behavioral) physical activity intervention
Number of subjects: 80
Study 28108936 — intervention group
Group type: COMPARATOR
Intervention: TRAD (traditional exercise therapy)
Number of subjects: 80
Study 25395013 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk expression education and support intervention
Number of subjects: 40
Study 25395013 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study 25090937 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D speckle-tracking echocardiography
Number of subjects: 42
Study 23101492 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate 2mg/kg/day for three days
Number of subjects: 166
Study 23101492 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate 4mg/kg/day for three days
Number of subjects: 166
Study 23101492 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHA-PPQ)
Number of subjects: 166
Study 19100282 — intervention group
Group type: EXPERIMENTAL
Intervention: GP+ES+P group (General Practitioner + Exercise Scientist + Pedometer)
Number of subjects: 136
Study 19100282 — intervention group
Group type: COMPARATOR
Intervention: GP group (General Practitioner only)
Number of subjects: 136
Study 19100282 — intervention group
Group type: EXPERIMENTAL
Intervention: GP+ES group (General Practitioner + Exercise Scientist)
Number of subjects: 136
Study 17446980 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour baseline intervention
Number of subjects: 3406
Study 17446980 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour baseline intervention plus two booster sessions
Number of subjects: 3406
Study 17446980 — intervention group
Group type: COMPARATOR
Intervention: Assessments only (control group)
Number of subjects: 3406
Study 15811058 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of periodontal dressing (Vocopac) with removal after 7-8 days (group 2)
Number of subjects: 36
Study 15811058 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of periodontal dressing (Vocopac) with removal after 3-4 days (group 1)
Number of subjects: 36
Study 15811058 — intervention group
Group type: COMPARATOR
Intervention: Control group without periodontal dressing
Number of subjects: 36
Study 12459350 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy (HT) - 4 months of goserelin (3.6 mg every 4 weeks) and flutamide (250 mg t.i.d.) before and during RT
Number of subjects: 456
Study 12459350 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy (HT)
Number of subjects: 456
Study 12459350 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 456